These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 12746761

  • 1. Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes.
    Forst T, Eriksson JW, Strotmann HJ, Bai S, Brunelle R, Gulliya KS, Gack S, Gudat U.
    Exp Clin Endocrinol Diabetes; 2003 Apr; 111(2):97-103. PubMed ID: 12746761
    [Abstract] [Full Text] [Related]

  • 2. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI, Străchinariu R, Farcaşiu E, Milicevic Z, Teodorescu G.
    Rom J Intern Med; 2003 Apr; 41(2):153-62. PubMed ID: 15526500
    [Abstract] [Full Text] [Related]

  • 3. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents.
    Ross SA, Zinman B, Campos RV, Strack T, Canadian Lispro Study Group.
    Clin Invest Med; 2001 Dec; 24(6):292-8. PubMed ID: 11767232
    [Abstract] [Full Text] [Related]

  • 4. The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes.
    Galic E, Vrtovec M, Bozikov V, Schwarzenhofer M, Milicevic Z.
    Med Sci Monit; 2005 Dec; 11(12):PI87-92. PubMed ID: 16319804
    [Abstract] [Full Text] [Related]

  • 5. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W.
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P, Sitagliptin Study 019 Group.
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [Abstract] [Full Text] [Related]

  • 7. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 8. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure.
    Zargar AH, Masoodi SR, Laway BA, Wani AI, Bashir MI.
    J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116
    [Abstract] [Full Text] [Related]

  • 9. Postprandial versus preprandial dosing of biphasic insulin aspart in elderly type 2 diabetes patients.
    Warren ML, Conway MJ, Klaff LJ, Rosenstock J, Allen E.
    Diabetes Res Clin Pract; 2004 Oct; 66(1):23-9. PubMed ID: 15364158
    [Abstract] [Full Text] [Related]

  • 10. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a controlled proof-of-concept study.
    Hausmann M, Dellweg S, Osborn C, Heinemann L, Buchwald A, Rosskamp R, Genova P, Heise T.
    Diabetes Obes Metab; 2006 Sep; 8(5):574-80. PubMed ID: 16918593
    [Abstract] [Full Text] [Related]

  • 11. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
    Tan MH, Johns D, Strand J, Halse J, Madsbad S, Eriksson JW, Clausen J, Konkoy CS, Herz M, GLAC Study Group.
    Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
    [Abstract] [Full Text] [Related]

  • 12. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: Chinese PRESENT study.
    Gao Y, Guo XH, Vaz JA, PRESENT Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):33-40. PubMed ID: 18494806
    [Abstract] [Full Text] [Related]

  • 13. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus.
    Schwartz S, Zagar AJ, Althouse SK, Pinaire JA, Holcombe JH.
    Clin Ther; 2006 Oct; 28(10):1649-57. PubMed ID: 17157120
    [Abstract] [Full Text] [Related]

  • 14. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
    Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.
    Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
    [Abstract] [Full Text] [Related]

  • 15. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients.
    Pala L, Mannucci E, Dicembrini I, Rotella CM.
    Diabetes Res Clin Pract; 2007 Oct; 78(1):132-5. PubMed ID: 17445933
    [Abstract] [Full Text] [Related]

  • 16. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
    Ceriello A, Del Prato S, Bue-Valleskey J, Beattie S, Gates J, de la Peña A, Malone J.
    J Diabetes Complications; 2007 Oct; 21(1):20-7. PubMed ID: 17189870
    [Abstract] [Full Text] [Related]

  • 17. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 18. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs.
    Yang W, Ji Q, Zhu D, Yang J, Chen L, Liu Z, Yu D, Yan L.
    Diabetes Care; 2008 May; 31(5):852-6. PubMed ID: 18268073
    [Abstract] [Full Text] [Related]

  • 19. Insulin lispro improves postprandial glucose control in patients with diabetes mellitus.
    Skrha J, Smahelová A, Andĕl M, Vrtovec M, Subić J, Kreze A, Vozar J, Korecová M, de Verga V, Wyatt J, Metcalfe S, Ristić S.
    Sb Lek; 2002 May; 103(1):15-21. PubMed ID: 12448933
    [Abstract] [Full Text] [Related]

  • 20. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study.
    Meneghini L, Koenen C, Weng W, Selam JL.
    Diabetes Obes Metab; 2007 Nov; 9(6):902-13. PubMed ID: 17924873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.